Table 1.
Patient characteristics regarding underlying disease (malignant vs. non-malignant).
| Number of patients | Malignant n = 91 (%) | Non-malignant n = 48 (%) | p (x2 test/test) |
|---|---|---|---|
| Median age at HSCT in years (range) | 11.1 (1–23.8) | 5.6 (0.1–24.8) | <0.0001 |
| Male | 63 (69) | 28 (58) | n.s. |
| Female | 28 (31) | 20 (42) | |
| Conditioning regimen | |||
| MAC | 75 (82) | 3 (6) | 0.0001 |
| RIC | 16 (18) | 45 (94) | |
| TBI containing | 60 (66) | 2 (4) | 0.0001 |
| TBI+MAC | 57 (95) | 0 | 0.0053 |
| TCD ex vivo | 6 (7) | 15 (30) | 0.0003 |
| Stem cell donors | |||
| MRD | 34 (37) | 17 (35) | n.s. |
| MUD | 52 (57) | 21 (44) | n.s. |
| MMRD | 3 (3) | 8 (16) | 0.0081 |
| MMUD | 2 (2) | 2 (4) | n.s. |
| Stem cell source | |||
| Bone marrow | 71 (78) | 27 (56) | 0.0075 |
| PBSCs | 20 (22) | 21 (44) | |
| Median number of CD34+ cells × 106/kg (range) | 6.0 (0.4–62) | 10.7 (0.24–40) | <0.0001 |
| Post-transplant immunosuppressive prophylaxis | |||
| No GVHD prophylaxis | 2 (2) | 3 (6) | n.s. |
| CsA only | 37 (41) | 13 (27) | n.s. |
| CsA+MTX | 40 (44) | 4 (8) | 0.0001 |
| CsA+MMF | 10 (11) | 23 (48) | 0.0001 |
| CsA+MTX+MMF | 1 (1) | 3 (6) | n.s. |
| CsA+FK506 | 1 (1) | 0 | n.s. |
| +ATG* | 61 (64) | 44 (88) | 0.0018 |
| Acute GVHD | 66 (73) | 19 (40) | 0.0005 |
| Grade 0 | 25 (27) | 29 (60) | |
| Grade 0–I | 63 (69) | 43 (90) | 0.025 |
| Grade II–IV | 28 (42) | 5 (24) | 0.0825 |
| Chronic GVHD | 29 (30) | 9 (18) | n.s. |
| Median time from HSCT to onset of cGVHD in months (range) | 6 (3–18) | 10 (3–50) | n.s. |
*
ATG was given additionally to other conditioning medications.